Dr. Raghbir Kaur, DMD

NPI: 1679722920
Total Payments
$25,534
2024 Payments
$5,721
Companies
3
Transactions
27

Payment Breakdown by Category

Consulting$15,775 (61.8%)
Other$6,375 (25.0%)
Travel$2,866 (11.2%)
Food & Beverage$454.87 (1.8%)
Gifts$62.49 (0.2%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $15,775 4 61.8%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,375 2 25.0%
Travel and Lodging $2,866 12 11.2%
Food and Beverage $454.87 8 1.8%
Gift $62.49 1 0.2%

Top Paying Companies

Company Total Records Latest Year
Ultragenyx Pharmaceutical Inc. $19,756 21 $0 (2021)
Kyowa Kirin, Inc. $5,715 5 $0 (2024)
Ultradent Products Inc $62.49 1 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $5,721 5 Kyowa Kirin, Inc. ($5,659)
2023 $56.18 1 Kyowa Kirin, Inc. ($56.18)
2021 $3,375 2 Ultragenyx Pharmaceutical Inc. ($3,375)
2020 $7,725 3 Ultragenyx Pharmaceutical Inc. ($7,725)
2019 $8,656 16 Ultragenyx Pharmaceutical Inc. ($8,656)

All Payment Transactions

27 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
12/10/2024 Ultradent Products Inc Opalescence (Device) Gift Cash or cash equivalent $62.49 General
Category: Dental
10/24/2024 Kyowa Kirin, Inc. Crysvita (Drug) Consulting Fee Cash or cash equivalent $4,900.00 General
Category: fibroblast growth factor 23 (FGF23) blocking antibody.
10/24/2024 Kyowa Kirin, Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $602.20 General
Category: fibroblast growth factor 23 (FGF23) blocking antibody.
10/24/2024 Kyowa Kirin, Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $106.90 General
Category: fibroblast growth factor 23 (FGF23) blocking antibody.
10/24/2024 Kyowa Kirin, Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $49.67 General
Category: fibroblast growth factor 23 (FGF23) blocking antibody.
05/17/2023 Kyowa Kirin, Inc. Food and Beverage In-kind items and services $56.18 General
01/25/2021 Ultragenyx Pharmaceutical Inc. Consulting Fee Cash or cash equivalent $1,875.00 General
01/25/2021 Ultragenyx Pharmaceutical Inc. Consulting Fee Cash or cash equivalent $1,500.00 General
02/23/2020 Ultragenyx Pharmaceutical Inc. Cryvista (Drug) Consulting Fee Cash or cash equivalent $7,500.00 General
Category: XLH Metabolic Bone Disorder
02/23/2020 Ultragenyx Pharmaceutical Inc. Cryvista (Drug) Travel and Lodging In-kind items and services $143.69 General
Category: XLH Metabolic Bone Disorder
02/21/2020 Ultragenyx Pharmaceutical Inc. Cryvista (Drug) Food and Beverage In-kind items and services $81.62 General
Category: XLH Metabolic Bone Disorder
09/13/2019 Ultragenyx Pharmaceutical Inc. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,250.00 General
09/13/2019 Ultragenyx Pharmaceutical Inc. Travel and Lodging Cash or cash equivalent $152.00 General
09/13/2019 Ultragenyx Pharmaceutical Inc. Travel and Lodging Cash or cash equivalent $80.00 General
09/13/2019 Ultragenyx Pharmaceutical Inc. Travel and Lodging Cash or cash equivalent $60.00 General
09/13/2019 Ultragenyx Pharmaceutical Inc. Food and Beverage In-kind items and services $20.23 General
09/13/2019 Ultragenyx Pharmaceutical Inc. Travel and Lodging Cash or cash equivalent $19.50 General
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $4,125.00 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $676.61 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $505.11 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $348.00 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Food and Beverage In-kind items and services $123.00 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Travel and Lodging Cash or cash equivalent $122.62 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Food and Beverage In-kind items and services $67.58 General
Category: XLH
07/18/2019 Ultragenyx Pharmaceutical Inc. Crysvita (Drug) Food and Beverage In-kind items and services $62.98 General
Category: XLH

About Dr. Raghbir Kaur, DMD

Dr. Raghbir Kaur, DMD is a Pediatric Dentistry healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/11/2008. The National Provider Identifier (NPI) number assigned to this provider is 1679722920.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raghbir Kaur, DMD has received a total of $25,534 in payments from pharmaceutical and medical device companies, with $5,721 received in 2024. These payments were reported across 27 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($15,775).

Practice Information

  • Specialty Pediatric Dentistry
  • Location New York, NY
  • Active Since 09/11/2008
  • Last Updated 04/03/2013
  • Taxonomy Code 1223P0221X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1679722920

Products in Payments

  • Crysvita (Drug) $11,733
  • Cryvista (Drug) $7,725
  • Opalescence (Device) $62.49

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Pediatric Dentistry Doctors in New York